Protara Therapeutics, Inc. (NASDAQ:TARA) Receives $26.25 Average Target Price from Brokerages

Posted by Geri Gentry on Aug 11th, 2026

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $26.25.

A number of equities research analysts have issued reports on TARA shares. Oppenheimer boosted their target price on shares of Protara Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, May 20th. HC Wainwright reiterated a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Wall Street Zen upgraded Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, JPMorgan Chase & Co. dropped their price objective on Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th.

Get Our Latest Analysis on Protara Therapeutics

Institutional Investors Weigh In On Protara Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Persistent Asset Partners Ltd purchased a new stake in shares of Protara Therapeutics in the fourth quarter worth about $57,000. AXQ Capital LP purchased a new position in Protara Therapeutics during the fourth quarter valued at approximately $58,000. The Manufacturers Life Insurance Company purchased a new position in Protara Therapeutics during the fourth quarter valued at approximately $59,000. Empery Asset Management LP bought a new stake in Protara Therapeutics during the 4th quarter worth approximately $68,000. Finally, AQR Capital Management LLC bought a new stake in Protara Therapeutics during the 4th quarter worth approximately $78,000. 38.13% of the stock is currently owned by institutional investors.

Protara Therapeutics Stock Down 0.2%

NASDAQ TARA opened at $4.11 on Tuesday. The company’s 50 day moving average is $4.05 and its 200-day moving average is $5.07. Protara Therapeutics has a 12-month low of $2.97 and a 12-month high of $7.82. The firm has a market cap of $230.98 million, a P/E ratio of -3.07 and a beta of 1.50.

Protara Therapeutics (NASDAQ:TARA – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. Equities analysts expect that Protara Therapeutics will post -1.44 EPS for the current year.

Protara Therapeutics Company Profile

(Get Free Report)

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.